Biomay to use VTU's yeast-based tech for its allergen pipeline

By Dan Stanton contact

- Last updated on GMT

Biomay to use VTU's yeast-based tech for its allergen pipeline

Related tags: Dna, Gene

Biomay has licensed a yeast-based expression system from fellow Austrian biotech VTU Technologies to use for the commercial production of its recombinant allergens.

The deal will see Biomay use VTU’s Pichia pastoris​ protein technology to generate expression strains for the commercial production of its allergy vaccine pipeline.

Recombinant allergens are generally not more difficult to express than other recombinant proteins, but are dependent on the complexity of the protein, Biomay’s CEO Hans Huber told this publication.

“If a protein is not expressible /producible with established systems such as E.coli, VTU´s Pichia Technology often succeeds,”​ he added.

Thomas Purkarthofer, Head of Business Development at VTU Technology, added his company’s technology “is composed of different elements such as platform strains with different genetic backgrounds, libraries of promoter variants and a set of proprietary expression enhancing helper proteins assisting the synthesis of a given target protein,”​ which, from a productivity angle, sets it apart from other expression platforms available.

“VTU´s experienced development team is capable of exploiting this technological potential by comparing thousands of strains in minimum time by applying elaborated lab protocols for strain generation and cultivation,”​ he explained to Biopharma-Reporter.com.

Like other methylotrophic yeasts, Pichia pastoris​ can be cultured to high cell densities within a short time and in reasonably strong methanol solutions. This coupled with VTU’s synthetic AOX1 promoter libraries, which fine tunes’ gene expression by selecting the best match for a range of different combinations of promoters, allows production yields of over 20g/L.

According to Purkarthofer, Biomay has been granted access on a product-by-product basis, and VTU will receive royalties based on sales of the recombinant allergens.

The announcement comes three months after VTU extended a deal with Boehringer-Ingelheim​ which is using the expression system for both its proprietary biologics and for its customers through its CMO business.

Related news

Show more

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us

Products

View more

Webinars